Harder, Better, Faster, Stronger – How AAVs Went From Lab to Clinic, and How Charles Rivers’ nAAVigation™ Platform Helps Scientists Take Gene Therapy From Science Fiction to Life-Saving Cures

Published on :

Harder, Better, Faster, Stronger – How AAVs Went From Lab to Clinic, and How Charles Rivers’ nAAVigation™ Platform Helps Scientists Take Gene Therapy From Science Fiction to Life-Saving Cures By [….]

Weekly Quick Hits (BioHealth Capital Region) – Week of March 20, 2023

Published on :

Weekly Quick Hits (BioHealth Capital Region) – Week of March 20, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryMarch 24, 2023 Funding, Awards and Collaborations MacroGenics Earns $15 Million [….]

How Do We Actually Meet the Needs of the Evolving Life Science Workforce?

Published on :

A recent panel discussion at Bisnow’s May Mid-Atlantic Life Sciences & Biotech event further emphasized the point that we’ve been hearing time and time again – we need to do more to support and adequately prepare the workforce to fill not only the current life science positions but future needs as well.

In Conversation: Matthew Hewitt, Ph.D., Executive Director at Charles River Laboratories

Published on :

If you’re a scientist, chances are when you hear the name “Charles River Laboratories” (Charles River) you may initially think of their industry-leading research models which are a staple for research labs globally. But did you also know that Charles River offers a plethora of products and services for translational laboratories and life science companies alike that span across the drug development lifecycle?

Charles River Laboratories Completes Acquisition of Rockville’s Vigene Biosciences

Vigene Biosciences Expansion 245 New Jobs
Published on :

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes additional payments of up to $57.5 million, contingent on future performance.

Charles River Laboratories to Acquire Rockville’s Vigene Biosciences to Enhance Gene Therapy Capabilities

Published on :

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions.